HTG Introduces the HTG EdgeSeq Mouse miRNA Whole Transcriptome Assay

HTG Molecular Diagnostics (Nasdaq:HTGM) a provider of instruments, reagents, and services for molecular profiling applications, today announced the pre-launch introduction of the new HTG EdgeSeq Mouse miRNA Whole Transcriptome Assay with product availability for shipment expected in the fourth quarter of 2018.

As quoted in the press release:

The HTG EdgeSeq Mouse miRNA WTA is designed for use with disease mouse models, including oncology, to identify and quantify the expression of a wide range of miRNAs in a variety of sample types, including formalin‑fixed paraffin-embedded (FFPE) tissue. The probe content of this assay is expected to be based on the current miRBase version 22 and contains 1,690 unique mouse miRNAs, including mouse viral miRNAs.

“We are excited to expand the HTG EdgeSeq assay portfolio to include an assay specific for profiling mouse microRNAs for labs using mouse models in translational medicine discovery, preclinical and toxicology studies,” stated Mike Hrubiak, Senior Vice President of HTG’s Profiling Business Unit. “The assay is designed to provide researchers more molecular profiling tools for conducting pathway analysis using very small sample sizes. We are proud that our portfolio of HTG EdgeSeq gene expression assays is an important part of biomarker development and academic translational studies and look forward to a commercial launch in the fourth quarter of 2018.”

Click here to read the full press release.